-
Mouse OX40L mRNA: Assay Design Guide
2026-09-29
Explore EZ Cap™ Mouse CD252(OX40L) mRNA (m1Ψ, HA tag) through an assay-design framework built around transient ligand expression, HA-based verification, receptor-dependent controls, and functional T-cell readouts. The article also explains what the Cho et al. mRNA vaccination study supports—and what it does not establish for OX40L.
-
Miltefosine: From PI3K/Akt to Myeloid Recovery
2026-09-29
Miltefosine is emerging as more than a PI3K/Akt pathway inhibitor. New preclinical evidence shows that it can promote neutrophil differentiation through Ras/MEK/ERK signaling, creating a strategic opportunity for translational researchers studying leukopenia, oncology, and context-dependent pathway biology.
-
Verapamil Targets TXNIP in Osteoporosis
2026-09-28
The reference study identifies TXNIP as a pharmacologically actionable regulator of osteoporosis and shows that verapamil reduces ovariectomy-associated bone loss in mice. Its combination of human genetic association, cell-based assays, pathway analysis, and in vivo imaging supports a repurposing hypothesis while leaving clinical efficacy and target specificity unresolved.
-
Paroxetine Mesylate: A Guide to Causal Assay Design
2026-09-28
Paroxetine Mesylate is best understood as more than a selective serotonin reuptake inhibitor: its broader target profile can complicate interpretation of cellular experiments. This guide shows how to separate primary pharmacology from secondary effects and design more defensible research assays.
-
EGCG Nanoparticles Strengthen FLASH Radiotherapy
2026-09-27
A 2026 study reports that functionalized, self-assembled EGCG nanoparticles (BENPs) increase FLASH radiotherapy-associated reactive oxygen species and DNA damage, strengthening tumor-cell killing in 4T1 models. The findings also connect this radiosensitization strategy with changes in antitumor immune-cell populations, while leaving important questions about dose optimization, mechanism, and clinical transferability open.
-
SP2509 in AML Viability and Epigenetic Assays
2026-09-26
A scenario-based guide to using SP2509 (SKU B4894) in acute myeloid leukemia research, from compound preparation to interpretation of viability, apoptosis, and differentiation endpoints. It distinguishes the reported biochemical potency from cell-based effects and outlines practical controls for more interpretable experiments.
-
Methylprednisolone: Interpreting Glucocorticoid Bone Injury
2026-09-25
Methylprednisolone is a synthetic glucocorticoid receptor agonist used to study both inflammatory responses and glucocorticoid-associated bone injury. This article examines how to connect immune, osteoclast, vascular, and structural readouts without mistaking a model-induction effect for a complete disease mechanism.
-
AM251: CB1 Receptor Antagonist Workflows
2026-09-25
Use AM251 to test whether CB1 signaling contributes to a measured phenotype—not simply to label a response as cannabinoid-dependent. This practical guide connects nanomolar receptor potency with controls, assay choices, and cautious interpretation in neuroscience, metabolic, and cell-cycle studies.
-
Pregnenolone Carbonitrile in Cholestasis Research
2026-09-24
Pregnenolone Carbonitrile gives rodent liver studies a practical way to probe PXR-linked xenobiotic metabolism and cholestatic injury in the same experimental framework. A recent mouse study connects PXR activation with reduced hepatocyte pyroptosis, while careful species selection, vehicle controls, and endpoint pairing help keep interpretation rigorous.
-
GTP Solution (100 mM) for IVT mRNA Research
2026-09-24
GTP Solution (100 mM) is a high-purity Guanosine-5'-triphosphate stock for nucleotide-dependent molecular biology workflows. It can support in vitro transcription when the validated reaction requires GTP, but the cited p21 mRNA–LNP bladder cancer study does not establish use of this specific product.
-
IL-7, Human Recombinant: Evidence & Use
2026-09-23
IL-7, human recombinant (P1024) is listed by APExBIO, but the available product dossier does not specify its formulation or activity. This article distinguishes established IL-7 receptor biology from a cited SARS-CoV-2 protease study that does not test IL-7.
-
CRTC–CREB Sensing of Proteotoxic Stress in Drosophila
2026-09-23
The reference study shows that proteasome inhibition activates a protective CRTC–CREB transcriptional program through ROS and JNK signaling. Its combination of adult-fly compound screening, mammalian-cell validation, transcriptomics, and Huntington’s disease models provides a mechanistic framework for understanding how cells convert proteotoxic stress into adaptive gene expression.
-
WIP1, p38 MAPK, and Pyroptosis in Septic AKI
2026-09-22
The reference study identifies WIP1/PPM1D as a protective brake on p38 MAPK-driven pyroptosis in sepsis-associated acute kidney injury. By combining human tissue, mouse models, HK2 cells, and single-cell transcriptomics, it links WIP1 inhibition to stronger inflammatory cell-death signaling and reduced tubular-cell viability, while also defining important limitations for translation.
-
Total RNA Extraction Reagent in Ferroptosis Studies
2026-09-22
Total RNA Extraction Reagent (Trizol) can connect radiation biology with transcript-level evidence. This guide explains how to use RNA isolation strategically when investigating DHODH suppression, ferroptosis, and macrophage polarization after carbon-ion radiotherapy.
-
GTP Solution: Quality Control for p21 mRNA
2026-09-21
GTP Solution supports controlled RNA synthesis upstream of advanced p21 mRNA–LNP research. This guide connects Guanosine-5'-triphosphate quality, assay design, storage, and interpretation with the localized bladder cancer findings reported in the latest FASEB Journal study.